287 related articles for article (PubMed ID: 30487125)
21. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.
Munzert G; Kirchner D; Stobbe H; Bergmann L; Schmid RM; Döhner H; Heimpel H
Blood; 2002 Nov; 100(10):3749-56. PubMed ID: 12411322
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
23. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
[TBL] [Abstract][Full Text] [Related]
24. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
26. Biological and clinical implications of
Diop F; Moia R; Favini C; Spaccarotella E; De Paoli L; Bruscaggin A; Spina V; Terzi-di-Bergamo L; Arruga F; Tarantelli C; Deambrogi C; Rasi S; Adhinaveni R; Patriarca A; Favini S; Sagiraju S; Jabangwe C; Kodipad AA; Peroni D; Mauro FR; Giudice ID; Forconi F; Cortelezzi A; Zaja F; Bomben R; Rossi FM; Visco C; Chiarenza A; Rigolin GM; Marasca R; Coscia M; Perbellini O; Tedeschi A; Laurenti L; Motta M; Donaldson D; Weir P; Mills K; Thornton P; Lawless S; Bertoni F; Poeta GD; Cuneo A; Follenzi A; Gattei V; Boldorini RL; Catherwood M; Deaglio S; Foà R; Gaidano G; Rossi D
Haematologica; 2020; 105(2):448-456. PubMed ID: 31371416
[No Abstract] [Full Text] [Related]
27. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
28. RIPK2 promotes the progression of colon cancer by regulating BIRC3-mediated ubiquitination of IKBKG.
Zhang Z; Pan Y; Zhao Y; Ren M; Li Y; Lu G; He S
Exp Cell Res; 2023 Aug; 429(1):113644. PubMed ID: 37211186
[TBL] [Abstract][Full Text] [Related]
29. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
30. A20 undermines alternative NF-κB activity and expression of anti-apoptotic genes in Helicobacter pylori infection.
Lim MCC; Maubach G; Birkl-Toeglhofer AM; Haybaeck J; Vieth M; Naumann M
Cell Mol Life Sci; 2022 Jan; 79(2):102. PubMed ID: 35089437
[TBL] [Abstract][Full Text] [Related]
31. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
[TBL] [Abstract][Full Text] [Related]
32. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
Xu J; Zhou P; Wang W; Sun A; Guo F
J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
[TBL] [Abstract][Full Text] [Related]
33. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
[TBL] [Abstract][Full Text] [Related]
34. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
[TBL] [Abstract][Full Text] [Related]
35. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
36. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
Mansouri L; Sutton LA; Ljungström V; Bondza S; Arngården L; Bhoi S; Larsson J; Cortese D; Kalushkova A; Plevova K; Young E; Gunnarsson R; Falk-Sörqvist E; Lönn P; Muggen AF; Yan XJ; Sander B; Enblad G; Smedby KE; Juliusson G; Belessi C; Rung J; Chiorazzi N; Strefford JC; Langerak AW; Pospisilova S; Davi F; Hellström M; Jernberg-Wiklund H; Ghia P; Söderberg O; Stamatopoulos K; Nilsson M; Rosenquist R
J Exp Med; 2015 Jun; 212(6):833-43. PubMed ID: 25987724
[TBL] [Abstract][Full Text] [Related]
37. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
39. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
